Trial of thyroxine treatment for biochemically euthyroid patients has been approved

doi:10.1136/bmj.315.7120.1463

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

This article has a correction

Please see: Reduction in use of temazepam is factor in deaths related to overdose

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

E H McLaren, Consultant physiciana,
C J G Kelly, Specialist registrar in endocrinologya,
M A Pollock, Principal biochemista

^a Stobhill NHS Trust, Glasgow G21 3UW

Editor—Skinner et al's suggestion that patients with symptoms of hypothyroidism and normal results of thyroid function tests might benefit from treatment with thyroxine1 received considerable publicity in our local evening newspaper. As a result, several patients were referred to our clinic.

Since they complained of a considerable reduction in their quality of life, …